Sumitomo Dainippon Pharma
Focus: Sumitomo Dainippon Pharma is a Japan-headquartered public pharmaceutical company specializing in small-molecule therapeutics across endocrinology, nephrology, and neurology. The company maintains a commercial presence in the US with a portfolio of peak-stage products generating significant Part D revenue.
Profile data last refreshed 17h ago · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
0
About Sumitomo Dainippon Pharma
AI assessmentNot HiringNo open roles listed right now. Follow Sumitomo Dainippon Pharma to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Sumitomo Dainippon Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
1 imminent
ONAPGO
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$508M Part DStable
Peak15.7yr
Dominant revenue driver (51% of company) with longest patent protection; beta-3 adrenergic agonist addressing large OAB market.
Help build intelligence for Sumitomo Dainippon Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.